quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 12, 2026

Is It Too Late To Consider Exxon Mobil (XOM) After Its Strong 1-Year Rally?

View original at finance.yahoo.com
Is It Too Late To Consider Exxon Mobil (XOM) After Its Strong 1-Year Rally? Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The P/E ratio is a useful metric for evaluating Exxon Mobil as a profitable company, with investors accepting higher or lower P/E based on earnings growth expectations and risk assessment

    60% confidence

  • Exxon Mobil has a valuation score of 4 out of 6

    60% confidence

  • Exxon Mobil is undervalued by 49.1% based on a 2-Stage Free Cash Flow to Equity DCF model, with an estimated intrinsic value of $293.99 per share versus the current share price of approximately $149.68

    60% confidence

  • Recent headlines around Exxon Mobil have largely focused on its position in the global energy sector and investor interest in large integrated oil companies, shaping sentiment around the stock

    60% confidence

  • Exxon Mobil's projected free cash flow will grow from approximately $23.0 billion (TTM) to $48.6 billion by 2030, with intermediate annual projections between 2026 and 2035 feeding into the DCF calculation

    60% confidence

Data points we hold from this source

Exxon Mobil Corporation · margin-49.1 percent
Exxon Mobil Corporation · cash48.6 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Is It Too Late To Consider Exxon Mobil (XOM) After Its Strong 1-Year Rally? — Source | Via News | pt.VIA.NEWS